Filing Flows › Biofrontera (BFRI) › Q3 2025
Biofrontera (BFRI) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Biofrontera (BFRI) reported revenue of $7.0M for the third quarter 2025 (Q3 2025), -22% from a year earlier and -23% from the quarter before. Operating margin was -89.8%, net loss $6.6M (95.1% of revenue).
Biofrontera, Q3 2025: revenue $7.0M (-22% year over year), operating margin -89.8%, net loss $6.6M, operating cash flow −$3.8M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $7.0M | -23% | -22% |
| Operating profit | −$6.3M | — | — |
| Net earnings | −$6.6M | — | — |
| Operating cash flow | −$3.8M | — | — |
What changed
Revenue was $7.0M in Q3 2025, down 22% year over year and down 23% from the previous quarter.
Operating costs exceeded revenue by $6.3M, an operating margin of -89.8%. Total costs fell 5% while revenue fell 22%. The fastest-growing cost line was Research & development (+28%). The quarter ended with a net loss of $6.6M, wider than the previous quarter's $5.3M loss.
Operating cash flow was −$3.8M. Non-cash charges added back $21K of depreciation and amortization and $236K of share-based compensation. Working capital and other items added $2.6M. Capital expenditures of −$1K exceeded it, leaving free cash flow of −$3.8M.
Questions
What was Biofrontera's revenue in the third quarter 2025?
Biofrontera (BFRI) reported revenue of $7.0M for the third quarter 2025 (Q3 2025), -22% from a year earlier and -23% from the quarter before.
Was Biofrontera profitable in the third quarter 2025?
Operating loss was $6.3M (-89.8% of revenue) and net loss $6.6M.
Source: Biofrontera 10-Q on SEC EDGAR.